Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771063 | 0.90 | LRRK2 (0.54) | FGFR1FLT1MAP4K1ITKLRRK2 | |
| SCHEMBL5770987 | 0.86 | FGFR1 (0.53) | FGFR1FLT1MAP4K1JAK2JAK3 | |
| SCHEMBL5872977 | 0.86 | TNKS (0.46) | FGFR1FLT1MAP4K1LRRK2 | |
| SCHEMBL18930828 | 0.83 | FGFR1 (0.63) | FGFR1FLT1MAP4K1JAK2JAK3 | |
| SCHEMBL5872971 | 0.80 | KDM4E (0.44) | FGFR1FLT1JAK2ITKLRRK2 | |
| SCHEMBL5813034 | 0.76 | LRRK2 (0.55) | FGFR1FLT1MAP4K1ITKLRRK2 | |
| SCHEMBL5873090 | 0.75 | PLK4 (0.47) | FGFR1FLT1MAP4K1 | |
| SCHEMBL5774743 | 0.74 | IDO1 (0.43) | FGFR1FLT1JAK2ITKLRRK2 | |
| SCHEMBL5773591 | 0.73 | JAK2 (0.47) | JAK2JAK3ITKLRRK2 | |
| SCHEMBL5772793 | 0.72 | JAK2 (0.43) | FGFR1JAK2ITKMELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664040-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| WO-2005026162-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | FGFR1 3930/4885FLT1 4235/4885MAP4K1 2486/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | FGFR1 3930/4885FLT1 4235/4885MAP4K1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.